These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 3958489

  • 41. Effect of glucan on Leishmania major infection in BALB/c mice.
    Al Tuwaijri AS, Mahmoud AA, Al Mofleh IA, Al Khuwaitir SA.
    J Med Microbiol; 1987 Jun; 23(4):363-5. PubMed ID: 3585970
    [Abstract] [Full Text] [Related]

  • 42. The activity of nitrofurazone and furazolidone against Leishmania donovani, L. major and L. enriettii in vitro and in vivo.
    Neal RA, van Bueren J, Hooper G.
    Ann Trop Med Parasitol; 1988 Oct; 82(5):453-6. PubMed ID: 2855778
    [Abstract] [Full Text] [Related]

  • 43. Viscerotropic growth pattern of Leishmania tropica in BALB/c mice is suggestive of a murine model for human viscerotropic leishmaniasis.
    Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D.
    Korean J Parasitol; 2007 Dec; 45(4):247-53. PubMed ID: 18165706
    [Abstract] [Full Text] [Related]

  • 44. The route of Leishmania tropica infection determines disease outcome and protection against Leishmania major in BALB/c mice.
    Mahmoudzadeh-Niknam H, Khalili G, Abrishami F, Najafy A, Khaze V.
    Korean J Parasitol; 2013 Feb; 51(1):69-74. PubMed ID: 23467583
    [Abstract] [Full Text] [Related]

  • 45. Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals.
    el-On J, Hamburger AD.
    Trans R Soc Trop Med Hyg; 1987 Feb; 81(5):734-7. PubMed ID: 3449988
    [Abstract] [Full Text] [Related]

  • 46. Antileishmanial effect of rapamycin as an alternative approach to control Leishmania tropica infection.
    Khadir F, Taheri T, Habibzadeh S, Zahedifard F, Gholami E, Heidari-Kharaji M, Oryan A, Rafati S.
    Vet Parasitol; 2019 Dec; 276():108976. PubMed ID: 31739256
    [Abstract] [Full Text] [Related]

  • 47. Sinefungin as treatment for American Leishmania in sensitive BALB/c and resistant C57BL/6 mice.
    Avila JL, Rojas T, Monzón H, Convit J.
    Am J Trop Med Hyg; 1990 Aug; 43(2):139-45. PubMed ID: 2389821
    [Abstract] [Full Text] [Related]

  • 48. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice.
    Titus RG, Marchand M, Boon T, Louis JA.
    Parasite Immunol; 1985 Sep; 7(5):545-55. PubMed ID: 3877902
    [Abstract] [Full Text] [Related]

  • 49. Immunomodulation of murine leishmaniasis with cyclosporin A.
    Behforouz NC, Wenger CD.
    Adv Exp Med Biol; 1988 Sep; 239():379-84. PubMed ID: 3202041
    [No Abstract] [Full Text] [Related]

  • 50. Administration of beta-glucan following Leishmania major infection suppresses disease progression in mice.
    Goldman R, Jaffe CL.
    Parasite Immunol; 1991 Mar; 13(2):137-45. PubMed ID: 2052403
    [Abstract] [Full Text] [Related]

  • 51. Anti-leishmanial effect of itraconazole niosome on in vitro susceptibility of Leishmania tropica.
    Khazaeli P, Sharifi I, Talebian E, Heravi G, Moazeni E, Mostafavi M.
    Environ Toxicol Pharmacol; 2014 Jul; 38(1):205-11. PubMed ID: 24956400
    [Abstract] [Full Text] [Related]

  • 52. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment.
    el-On J, Sulitzeanu A, Schnur LF.
    Ann Trop Med Parasitol; 1991 Jun; 85(3):323-8. PubMed ID: 1746981
    [Abstract] [Full Text] [Related]

  • 53. Mechanisms of immunity to leishmaniasis. IV. Significance of lymphatic drainage from the site of infection.
    Poulter LW, Pandolph CR.
    Clin Exp Immunol; 1982 May; 48(2):396-402. PubMed ID: 7105491
    [Abstract] [Full Text] [Related]

  • 54. Variants with reduced virulence derived from Leishmania major after mutagen treatment.
    Marchand M, Daoud S, Titus RG, Louis J, Boon T.
    Parasite Immunol; 1987 Jan; 9(1):81-92. PubMed ID: 3562060
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Effectiveness of prophylactic inoculations against cutaneous leishmaniasis].
    Dobrzhanskaia RS, Khuseĭinova KhKh, Sukhanov TA, Saf'ianova VM, Emel'ianova LP.
    Vestn Dermatol Venerol; 1988 Jan; (3):15-20. PubMed ID: 3381577
    [No Abstract] [Full Text] [Related]

  • 57. The kinetics and quality of acquired resistance in self-healing and metastatic leishmaniasis.
    Poulter LW.
    Clin Exp Immunol; 1979 Apr; 36(1):30-7. PubMed ID: 380855
    [Abstract] [Full Text] [Related]

  • 58. [Attempt at cryogenic preservation of the amastigote stage of Leishmania major in the ear skin of experimentally infected golden hamsters (Mesocricetus auratus)].
    Passova OM, Rakhimov KhT.
    Med Parazitol (Mosk); 1986 Apr; (4):45-6. PubMed ID: 3762496
    [No Abstract] [Full Text] [Related]

  • 59. Pathophysiology of experimental leishmaniasis: pattern of development of metastatic disease in the susceptible host.
    Hill JO.
    Infect Immun; 1986 May; 52(2):364-9. PubMed ID: 3699885
    [Abstract] [Full Text] [Related]

  • 60. Immunoprophylaxis in BALB/c mice: a model for development of protection against primary and secondary infection with Leishmania major.
    Mock BA, Fortier AH, Meltzer MS, Nacy CA.
    Curr Top Microbiol Immunol; 1985 May; 122():107-14. PubMed ID: 4042672
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.